Posted on 02/12/2009 in Pharmaceutical Company Product News Ipsen and Roche have revealed that a treatment they collaborated on - taspoglutide - yielded a positive outcome during a clinical study.
Taspoglutide went head-to-head in the trial with sitagliptin (Januvia) and a placebo therapy for the management of diabetes.
According to the Ipsen, the drug is similar to the natural hormone GLP-1 - which has a key role in blood sugar regulation.
Taspoglutide was generally well-tolerated, with the most common adverse events reported including nausea and vomiting.
Roche acquired the licensing for taspoglutide from Ipsen in 2006 and gained exclusive worldwide rights to develop and market the therapy, except in Japan and France.
Last week, Ipsen announced the beginning of a study into its investigational first-in-class steroid sulfatase inhibitor BN83495.
As part of the controlled international, multi-centre randomised study, the drug's ability to treat advanced endometrial cancer will be examined by the firm. Other news stories from 02/12/2009
Read more in the Zenopa News Archive
How this news is generated
|
